期刊论文详细信息
Clinical Chemistry
Identification of Males with Cryptic Fragile X Alleles by Methylation-Specific Quantitative Melt Analysis
Lorena Santa Maria4  Xin Li5  Paulina Morales4  David Francis5  David J. Amor3  Desiree Du Sart5  Solange M. Aliaga1  Bianca Curotto4  Cesar Trigo2  Víctor Faundes4  Angelica M. Alliende2  David E. Godler5  Howard R. Slater3  Isabel Salas2 
[1] Cyto-molecular Diagnostic Research Laboratory, Victorian Clinical Genetics Services and Murdoch Children`s Research Institute, Royal Children`s Hospital, Melbourne, Victoria, Australia;Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia;Cytogenetics and Molecular Laboratory, Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile;;Centre for Diagnosis and Treatment of Fragile X Syndrome, INTA University of Chile, Santiago, Chile.Cyto-molecular Diagnostic Research Laboratory, Victorian Clinical Genetics Services and Murdoch Children`s Research Institute, Royal Children`s Hospital, Melbourne, Victoria, Australia;Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia;;Cytogenetics and Molecular Laboratory, Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile;Centre for Diagnosis and Treatment of Fragile X Syndrome, INTA University of Chile, Santiago, Chile.Cyto-molecular Diagnostic Research Laboratory, Victorian Clinical Genetics Services and Murdoch Children`s Research Institute, Royal Children`s Hospital, Melbourne, Victoria, Australia;
DOI  :  10.1373/clinchem.2015.244681
学科分类:过敏症与临床免疫学
来源: American Association for Clinical Chemistry
PDF
【 摘 要 】

BACKGROUND: FMR1 full mutations (FMs) (CGG expansion >200) in males mosaic for a normal (<45 CGG) or gray-zone (GZ) (45–54 CGG) allele can be missed with the standard 2-step fragile X syndrome (FXS) testing protocols, largely because the first-line PCR tests showing a normal or GZ allele are not reflexed to the second-line test that can detect FM.METHODS: We used methylation-specific quantitative melt analysis (MS-QMA) to determine the prevalence of cryptic FM alleles in 2 independent cohorts of male patients (994 from Chile and 2392 from Australia) referred for FXS testing from 2006 to 2013. All MS-QMA–positive cases were retested with commercial triplet primed PCR, methylation-sensitive Southern blot, and a methylation-specific EpiTYPER-based test.RESULTS: All 38 FMs detected with the standard 2-step protocol were detected with MS-QMA. However, MS-QMA identified methylation mosaicism in an additional 15% and 11% of patients in the Chilean and Australian cohorts, respectively, suggesting the presence of a cryptic FM. Of these additional patients, 57% were confirmed to carry cryptic expanded alleles in blood, buccal mucosa, or saliva samples. Further confirmation was provided by identifying premutation (CGG 55–199) alleles in mothers of probands with methylation-sensitive Southern blot. Neurocognitive assessments showed that low-level mosaicism for cryptic FM alleles was associated with cognitive impairment or autism.CONCLUSIONS: A substantial number of mosaic FM males who have cognitive impairment or autism are not diagnosed with the currently recommended 2-step testing protocol and can be identified with MS-QMA as a first-line test.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201912020396660ZK.pdf 4397KB PDF download
  文献评价指标  
  下载次数:1次 浏览次数:1次